ad

Epigral Share Price Target 2027: Can It Reach Rs 1,353? Base Case at Rs 1,129

Epigral share price Rs 949.05 (17 November 2026). Base target Rs 1,129, bull Rs 1,353, downside risk Rs 753. PE 14.25. 52W range Rs 807.00 to Rs 1,535.20.


17 Nov 2026 • 9:32 am

Epigral Share Price Target 2027: Can It Reach Rs 1,353? Base Case at Rs 1,129

Quick Answer

The Epigral share price target for 2027 is Rs 1,129, about 19.0% above the current price of Rs 949.05. The bull case is Rs 1,353, and the downside risk level, which is not a target, is Rs 753. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 27.8%, with the stock holding its PE of 14.25. These are model-based estimates built from reported financials, not guaranteed outcomes.

Investors weighing a Epigral target price for 2027 should start with where the stock sits today. At Rs 949.05 on 17 November 2026, it is 38.2% below its 52-week high of Rs 1,535.20 and 17.6% above its 52-week low of Rs 807.00. That range spans 90% from low to high, so the entry point matters as much as the Epigral price forecast itself.

This article builds the Epigral share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.

Click Here – Get Free Investment Predictions

Epigral Stock Analysis: Company Overview and Key Stats

Epigral (NSE: EPIGRAL) has a market capitalisation of Rs 4,060 crore. In FY26 it reported revenue of Rs 2,542 crore and net profit of Rs 331.97 crore. The table collects the figures the Epigral share price target is built on.

Metric Value
Company Epigral
NSE Ticker EPIGRAL
CMP (17 November 2026) Rs 949.05
52-Week High Rs 1,535.20
52-Week Low Rs 807.00
Market Cap Rs 4,060 crore
PE Ratio (TTM) 14.25
Industry PE 33.54
Price to Book 1.72
Return on Equity 12.05%
Debt to Equity 0.24
EPS (TTM) Rs 66.03
Dividend Yield 0.53%
12-Month Base Target Rs 1,129
Bull Case Rs 1,353
Downside Risk Level (not a target) Rs 753

Why Is Epigral Share Price Target Set at Rs 1,129 for 2027?

The arithmetic is short. Trailing EPS of Rs 66.03 grown for one year gives a forward EPS estimate of Rs 79.24, and multiplying it by the unchanged PE of 14.25 gives the Rs 1,129 base-case Epigral stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.

Earnings Growth Behind the Epigral Target Price: Five Years of Results

Epigral grew revenue from Rs 1,555 crore in FY22 to Rs 2,542 crore in FY26, a compound annual growth rate of 13.1%. Net profit grew more slowly, from Rs 252.79 crore to Rs 331.97 crore (7.0% a year), which points to margin pressure alongside the sales growth.

Financial Year Revenue (Rs Cr) Net Profit (Rs Cr) EPS (Rs) Dividend per Share (Rs)
FY22 1,555.05 252.79 60.84 0.00
FY23 2,196.38 353.29 85.03 5.00
FY24 1,935.76 195.87 47.14 5.00
FY25 2,565.34 357.69 84.68 6.00
FY26 2,542.16 331.97 76.95 5.00

FY26 revenue growth was -0.9%, slower than the four-year average of 13.1%, and net profit moved down 7.2%. EPS rose from Rs 47.14 in FY24 to Rs 76.95 in FY26. The FY27 outlook for the Epigral price target depends on whether that EPS estimate keeps compounding.

Margins and the Latest Quarter

Epigral converted 13.1% of FY26 revenue into net profit, against 13.9% in FY25, within a five-year range of 10.1% to 16.3%. EBITDA margin was 22.9% in FY26 versus 28.3% in FY25.

In the September 2026 quarter, revenue was Rs 751.81 crore, up 27.6% from the same quarter a year earlier, while net profit of Rs 65.08 crore was up 27.1%. EBITDA came in at Rs 141.93 crore, up 5.8% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Epigral stock target holds.

Balance Sheet and Cash Flow

Debt to equity stands at 0.24, and shareholders' equity grew from Rs 725.97 crore in FY22 to Rs 2,221 crore in FY26. Operating cash flow in FY26 was Rs 435.53 crore against capital expenditure of Rs 394.15 crore, leaving free cash flow of Rs 41.38 crore, or 1.0% of the current market capitalisation. In FY25 free cash flow was Rs 245.87 crore.

Valuation Check for the Epigral Stock Target: PE, Price to Book and ROE

At a PE of 14.25 against an industry PE of 33.54, Epigral trades at a discount to its industry. Price to book is 1.72 on a book value of Rs 548.13 per share, and return on equity is 12.05%. A PE of 14.25 equals an earnings yield of 7.0%, and the FY26 dividend of Rs 5.00 per share gives a yield of 0.53%.

Shareholding Pattern and Institutional Holding

Promoters held 68.83% of Epigral in September 2026, and promoter holding has stayed near 68.83% since September 2025. Foreign institutional investors (FII) held 0.99% and domestic institutions (DII) held 4.90%, which puts total institutional holding at 5.89%. FII holding fell from 2.71% in September 2025 to 0.99% in September 2026. Public shareholders own the remaining 25.29%.

Epigral Share Price Targets for the Short Term and 12 Months

Short Term Epigral Stock Target Levels: Technical Setup

At Rs 949.05 on 17 November 2026, Epigral trades below its 50-day simple moving average of Rs 1,011.97 and below its 200-day exponential moving average of Rs 1,131.95. The 14-day RSI reads 58.2, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 1,011.97 (50-day simple moving average) and the nearest support is Rs 807.00 (52-week low). A sustained move above Rs 1,011.97 would improve the short-term setup, while a close below Rs 807.00 would shift attention to the next support.

12 Month Epigral Target Price for 2027

The 12-month target of Rs 1,129 means a move of 19.0% up from Rs 949.05 over the next 12 months. It would still leave the stock 26.5% below its 52-week high of Rs 1,535.20. Anyone checking the Epigral share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.

How EPS Growth and PE Multiple Change the Epigral Target Price

EPS Growth PE 11.40 PE 14.25 PE 16.39
0.0% (EPS Rs 66.03) Rs 753 Rs 941 Rs 1,082
20.0% (EPS Rs 79.24) Rs 903 Rs 1,129 Rs 1,299
25.0% (EPS Rs 82.54) Rs 941 Rs 1,176 Rs 1,353

Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Epigral price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.

Bull Case and Downside Risk for Epigral Stock Target in 2027

Bull Case Rs 1,353

The bull case Epigral price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 82.54, and a PE multiple that rises 15% to 16.39. That gives Rs 1,353, 42.6% above the current price and below the 52-week high of Rs 1,535.20.

Downside Risk Level Rs 753

The downside risk level is not a target. It assumes EPS stays flat at Rs 66.03 and the PE falls 20% to 11.40. That gives Rs 753, 20.7% below the current price and below the 52-week low of Rs 807.00.

Scenario EPS Growth PE Multiple Price (Rs) Change vs CMP
Bull Case 25.0% 16.39 Rs 1,353 +42.6%
Base Case 20.0% 14.25 Rs 1,129 +19.0%
Downside Risk 0.0% 11.40 Rs 753 -20.7%

Key Risks to the Epigral Target Price for 2027

Growth Slowdown Risk for the Epigral Price Target

Revenue in the September 2026 quarter was up 27.6% year on year, and FY26 revenue growth was -0.9%. If growth slows from here, the EPS estimate behind the Epigral stock target will need revising.

Liquidity and Size Risk

Epigral has a market capitalisation of Rs 4,060 crore. Institutional holding is 5.89%, and promoters hold 68.83%. Stocks of this size can move sharply on small volumes, and exits can take longer than entries.

Valuation and Margin Risk

Net margin was 13.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 14.25 versus an industry PE of 33.54, a de-rating toward the downside-risk PE of 11.40 would cut the price even if earnings hold.

Market and Technical Risk

Technical indicators add short-term risk: the 14-day RSI is 58.2 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time. That applies to any Epigral stock target, however carefully it is built.

How to Invest in Epigral

Start with the live price and volume. Any Epigral share price target is only as current as the data behind it, and the data here is as of 17 November 2026, so refresh the Rs 949.05 price before acting on any level.

Next, review the fundamentals yourself. The Univest Screener lets you check Epigral's PE, ROE, debt and shareholding in one place.

Check Epigral fundamentals on the Univest Screener

Then compare the three Epigral target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.

Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.

Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.

Download the Univest iOS App or Univest Android App to track Epigral live price and get daily stock recommendations.

Conclusion

The Epigral share price target for 2027 is Rs 1,129 in the base case, with Rs 1,353 as the bull case. The support for that view is arithmetic you can check: EPS grew 27.8% a year over FY24 to FY26, and the stock trades at a PE of 14.25. The risks are equally concrete, including a valuation that can de-rate if growth disappoints and a downside scenario that cuts the price 21% if earnings stall. Use these numbers as a framework for judging the Epigral price target, check them against the latest filings, and size any position to your own risk appetite.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Epigral Share Price Target 2027

What is the Epigral share price target for 2027?

Ans. The base-case Epigral share price target for 2027 is Rs 1,129, which is 19.0% above the price of Rs 949.05 on 17 November 2026. The bull case is Rs 1,353 and the downside risk level, which is not a target, is Rs 753. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.

What is the Epigral share price today?

Ans. As of 17 November 2026, before market open, Epigral (NSE: EPIGRAL) is quoted at Rs 949.05, which is its last closing price from the previous session. That is 38.2% below the 52-week high of Rs 1,535.20 and 17.6% above the 52-week low of Rs 807.00. The market capitalisation of Rs 4,060 crore places it among small-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.

Is Epigral a buy or sell at the current price?

Ans. The data points both ways. On the positive side, EPS has grown 27.8% a year over FY24 to FY26 and the base case implies 19.0% upside; on the cautious side, the stock sits 38.2% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 753 is 21% below the current price. Whether Epigral fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.

What are the bull case target and downside risk level for Epigral shares?

Ans. The bull case in the Epigral share price target for 2027 is Rs 1,353, which assumes 25.0% EPS growth and a PE of 16.39, a 15% re-rating from today's multiple. That is 42.6% above the current price and below the 52-week high of Rs 1,535.20. The downside risk level is Rs 753, which assumes flat EPS and a PE of 11.40, 20% lower than today. It sits 20.7% below the current price and below the 52-week low of Rs 807.00, and it marks a risk to watch, not a target.

What are the main risks to the Epigral price target?

Ans. Four risks matter most for the Epigral share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 4,060 crore, the stock can move sharply on small volumes, and exits can take longer than entries. A fall to the downside-risk PE of 11.40 would cut the price even if earnings hold.

What is the PE ratio of Epigral and how does it compare with the industry?

Ans. The PE ratio of Epigral is 14.25, against an industry PE of 33.54, which is a discount to the industry. Price to book is 1.72 and return on equity is 12.05%, and the PE equals an earnings yield of 7.0%. The base case holds the PE unchanged, so the Epigral share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.

Who owns Epigral, and what is the promoter holding?

Ans. Promoters held 68.83% of Epigral in September 2026. FII held 0.99%, DII held 4.90% and the public held 25.29%. Together the two institutional groups hold 5.89%. Shareholding is filed every quarter, so it is worth rechecking after each result.

What were Epigral's latest quarterly results?

Ans. In the September 2026 quarter, Epigral reported revenue of Rs 751.81 crore (up 27.6% year on year) and net profit of Rs 65.08 crore (up 27.1%). For comparison, FY26 full-year revenue growth was -0.9% and net profit moved down 7.2%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down